CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy

Starting soon

Conditions studied: Nasopharyngeal Carcinoma

In brief

This study aims to compare the efficacy of two treatment strategies-re-induction chemotherapy followed by radiotherapy versus direct radiotherapy-in patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not achieve a sufficient response (stable disease or disease progression) after two cycles of induction chemotherapy. The study will enroll patients who have completed two cycles of induction chemotherapy and have not achieved a partial or complete response. Participants will receive one of the two treatment options to evaluate their three-year progression-free survival (PFS) and other clinical outcomes.

Key facts

Study ID

NCT07399158

Run by

Fujian Cancer Hospital

People needed

223

Starts

2026-02-01

Expected to finish

2030-02-01

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: 18 to 70 years old.
• Histologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II/III).
• Initial treatment with no distant metastasis: Locally advanced nasopharyngeal carcinoma (according to the AJCC/UICC 9th edition staging, stage II-III, i.e., T3-4N0-3M0 or T1-2N2-3M0).
• Completion of two cycles of standard induction chemotherapy (such as TPF, GP, TP, etc.).
• Post-induction chemotherapy evaluation: Disease stability (SD) or disease progression (PD) after two cycles of induction chemotherapy, as assessed by RECIST 1.1 criteria, based on enhanced MRI of the nasopharynx.
• ECOG Performance Status (PS): 0-1.
• Bone marrow, liver, and kidney function: Sufficient to tolerate concurrent chemoradiotherapy (specific criteria to be referenced).
• Informed consent: Voluntary participation in the study and signing of written informed consent.

You may not qualify if…

• History of head and neck tumor radiotherapy or any other malignant cancer history (except for cured non-melanoma skin cancer).
• Partial response (PR) or complete response (CR) after induction chemotherapy.
• Severe uncontrolled comorbidities, such as unstable angina, congestive heart failure, severe chronic obstructive pulmonary disease (COPD), or uncontrolled diabetes mellitus.
• Active infection or severe immunodeficiency diseases.
• Pregnant or breastfeeding women.
• Any mental or social disorders that may interfere with study evaluation or compliance.
• Other conditions deemed by the investigator to be unsuitable for participation in the study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.